TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Feasibility and Accuracy of a Novel Xpert Cartridge for Rapid Molecular Detection of Drug Resistant Mycobacterium Tuberculosis in Sputum
Brief Summary: Consenting adults will be interviewed for demographic and medical information, and then will be asked to provide two expectorated sputum specimens. In the study laboratory, sputa will be tested using conventional and investigational diagnostic tests for tuberculosis.


Options:
A: Inclusion criteria:

1. Any ventilated patients over 18 years of age with suspected TB (suggestive pulmonary infiltrates, a history of constitutional symptoms preceding the ICU admission, or patients known or suspected to be infected with the human immunodeficiency virus (HIV)).

Exclusion criteria:

1. Patients known to have active TB or to already be on antituberculous medication.
B: Inclusion Criteria:

* Individuals must meet all of the following inclusion criteria in order to be eligible to participate:

  * Age ≥ 19 years (age of majority) if enrolled in South Korea; age ≥ 18 years (age of majority) if enrolled in China
  * Provision of informed consent
  * Clinical signs and/or symptoms suggestive of pulmonary tuberculosis
  * Meets one of the following criteria:

A. Suspected or confirmed new pulmonary tuberculosis case who has received anti-tuberculosis drugs for less than 3 (three) days (target enrollment for Group A is approximately 50 participants).

B. Confirmed pulmonary tuberculosis with documented rifampin resistance, who has received anti-tuberculosis drugs for 31 days or less C. History of prior tuberculosis PLUS ongoing signs and/or symptoms of pulmonary tuberculosis PLUS suspected drug resistance

Exclusion Criteria:

* Inability to provide a sputum specimen
C: Inclusion Criteria:

* HIV infection
* Fulfills criteria for antiretroviral therapy (CD4 cell count below 350 cells/ml and/or WHO stage IV)
* Residence in study uptake area
* Written informed consent to participation and to tracing in case of defaulting

Exclusion Criteria:

* Ongoing or previous antiretroviral therapy
* Treatment for active tuberculosis for more than two weeks
D: Inclusion Criteria:

* HIV-infected (1x rapid HIV test positive)
* Considered TB suspect by attending doctor (must comprise at least 1 of the following: current fever or cough, drenching night sweats, self-reported LOW)
* Illness severity sufficient to warrant hospitalization
* ≥18 years old
* Provision of informed consent

Exclusion Criteria:

* HIV-uninfected
* Patients receiving any anti-TB medication in the 60 days prior to testing
* Unable to provide 30mls urine
* Inability to provide informed consent

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomized, Double Blind, Placebo Controlled Trial Comparing the Impact of a Combined Package of Interventions vs Placebo in the Treatment of Sub-clinical Environmental Enteropathy in Rural Malawian Children
Brief Summary: Randomized, double-blind, placebo controlled trial of a combined intervention of zinc, albendazole, and multiple micronutrients in improving environmental enteropathy in Malawian children.


Options:
A: Inclusion Criteria:

* 6 to 59 months of age
* Not malnourished
* Diagnosis of malaria and/or diarrhoea and/or LRTI
* Intending to remain in area for the duration of the 6 month follow-up
* Living within approximately 60 minutes walking distance from the clinic
* Informed consent from a guardian\*

Exclusion Criteria:

* Child is exclusively breastfeeding
* Child is severely malnourished
* Presence of 'General Danger Signs'
* Presence of severe disease (including severe malaria, severe LRTI, severe diarrhoea)
* Needing hospitalisation for any reason
* Known history of allergy to the nutritional supplementation
* Having a sibling enrolled in the study\*
B: Inclusion Criteria:

1. Aged 12-36 months;
2. Residing in the study area;
3. Planning to be in the area for the duration of the intervention and follow-up;
4. Study protocol accepted and informed consent given by at least one parent or guardian

Exclusion Criteria:

1. Known or reported allergy to dihydroartemisinin, piperaquine, benzimidazole drugs or praziquantel;
2. A sibling from the same household already randomised to intervention;
3. Severely malnourished (weight-for-height z-score \< -3 SD) (for ethical reasons);
4. Presence of fever (axillary temperature ≥ 37.5 ºC) (to avoid inflammation-induced effects on iron status markers);
5. Presence of reported or suspected systemic disorder (e.g. HIV infection, sickle cell disease) (to avoid inflammation-induced effects on iron status markers and to avoid attrition);
6. Missed one or several doses of the 3-day course of dihydroartemisinin-piperaquine (to ensure that participants are protected against malaria for the duration of the iron intervention);
7. No blood sample collected, or blood volume collected \< 5 mL;
8. Haemoglobin concentration \< 70 g/L (to prevent severe anaemia).
C: Inclusion Criteria:

* children residing in catchment area of Limela, Machinga District, Malawi
* aged 12-35 months
* youngest eligible child in each household

Exclusion Criteria:

* severe acute malnutrition
* severe chronic illness
* children unable to drink 20 mL of dual sugar solution
* children in need of acute medical treatment for illness or injury at time of enrollment
D: Inclusion Criteria:

* Singleton Children or one child per home

Exclusion Criteria:

* Currently taking iron supplements
* Mid upper arm circumference (MUAC) or less than 11.5 cm
* Suspected severe anemia
* Known case of haemoglobinopathy
* History of repeated blood transfusion
* Current pneumonia
* Current fever
* Acute diarrhea

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomized, Double Blind, Placebo Controlled Trial Comparing the Impact of a Combined Package of Interventions vs Placebo in the Treatment of Sub-clinical Environmental Enteropathy in Rural Malawian Children
Brief Summary: Randomized, double-blind, placebo controlled trial of a combined intervention of zinc, albendazole, and multiple micronutrients in improving environmental enteropathy in Malawian children.


Options:
A: Inclusion Criteria:

* infants living in the study area
B: Inclusion Criteria:

* children residing in catchment area of Limela, Machinga District, Malawi
* aged 12-35 months
* youngest eligible child in each household

Exclusion Criteria:

* severe acute malnutrition
* severe chronic illness
* children unable to drink 20 mL of dual sugar solution
* children in need of acute medical treatment for illness or injury at time of enrollment
C: Inclusion Criteria:

* recovered from moderate acute malnutrition, as defined by mid-upper arm circumference (MUAC) of 11.5-12.4 cm

Exclusion Criteria:

* not permanent resident in vicinity of site
* severe chronic illness
* receiving other supplementary food or participating in other research
D: Inclusion Criteria:

* Deliver at Hospital Iquitos
* Plan to reside in Iquitos or neighbouring area for the next 24 months
* Able to communicate in Spanish

Exclusion Criteria:

* Deliver multiples
* Delivery a stillborn or an infant with a serious congenital medical condition
* Transfered to another hospital prior to discharge

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Enhancing Assertive Community Treatment With Cognitive Behavioral Therapy and Social Skills Training for Schizophrenia.
Brief Summary: This project is an effectiveness trial comparing two psychosocial treatments for schizophrenia: Assertive Community Treatment (ACT) + Cognitive Behavioral Social Skills Training (CBSST) v. ACT, alone.


Options:
A: Inclusion Criteria:

* DSM-IV-diagnosis of schizophrenia or schizoaffective disorder at any stage of illness

Exclusion Criteria:

* Unstable assignment (at least 3 months) to an ACT team;
* Prior exposure to SST or CBT in the past 5 years
* Level of care required interferes with outpatient therapy (e.g., current hospitalization for psychiatric, substance use or physical illness).
B: Inclusion Criteria:

* DSM-IV diagnosis of schizophrenia, schizoaffective or schizophreniform disorder at the time of initial assessment
* Pre-treatment illness duration an average of 5 years, not to exceed 8 years
* Stable positive symptoms (e.g., if present do not grossly interfere with behavior such as command hallucinations or delusions)
* Currently maintained and compliant with prescribed antipsychotic medication
* Socially and cognitively disabled, e.g., meet criteria on a Cognitive Style Scale (score greater than or equal to 7), and Social Cognition Disability Scale (score greater than or equal to 12).

Exclusion Criteria:

* Alcohol/drug abuse or dependence that has significantly interfered with adjustment in the past two months (e.g., patients currently undergoing D and A treatment must successfully complete their recovery program prior to referral)
* Organic brain syndrome, including HIV illness (due to its effect on CNS function)
* IQ below 80 or language skills below the sixth grade level
* Medical contraindications that preclude an appropriate antipsychotic medication
* Persistent suicidality
C: Inclusion Criteria:

* DSM-IV diagnosis of schizophrenia or schizoaffective disorder at any stage of illness

Exclusion Criteria:

* Level of care required at baseline interferes with outpatient group therapy participation (e.g., partial or inpatient hospitalization for psychiatric illness, substance use, or physical illness)
* No case manager or care coordinator
* Medically or psychiatrically unstable for outpatient therapy
* Exposure to social skills training (SST), cognitive behavioral therapy (CBT), or dialectical behavioral therapy (DBT) within 5 years prior to study entry
D: Inclusion Criteria:

* Participants must be undergoing treatment for moderate to severe mental health problems.
* Participants must have an expressed desire to work.
* Participants must have sufficient Norwegian reading and writing skills.

Exclusion Criteria:

* Participants are not undergoing treatment for moderate to severe mental health problems.
* Participants do not have an expressed desire to work.
* Participants do not have sufficient Norwegian reading and writing skills.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Soft Bifocal Contact Lens Myopia Control
Brief Summary: This study will evaluate the use of two different bifocal contact lens add powers to prevent further nearsighted progression in children ages 7 to 11 years old. It is theorized that the profile of the bifocal lenses will decrease the amount of change in nearsightedness that the children experience.


Options:
A: Inclusion Criteria:

* 7 to 11 years, inclusive, at baseline examination
* -0.75 to -5.00 D, inclusive, spherical component, cycloplegic autorefraction
* ≤1.00 DC, cycloplegic autorefraction
* ≥ 2.00 D difference between the sphere components of the two eyes (anisometropia), cycloplegic autorefraction
* 0.1 logMAR or better best-corrected visual acuity in each eye
* 0.1 logMAR or better visual acuity OU distance and near with a +2.50 D add contact lens
* +2.50 D add lens provides adequate fit with respect to movement and centration

Exclusion Criteria:

* Eye disease or binocular vision problems (e.g., strabismus, amblyopia, oculomotor nerve palsies, corneal disease, etc.)
* Systemic disease that may affect vision, vision development, or contact lens wear (eg, diabetes, Down syndrome, etc.)
* Previous gas permeable, soft bifocal, or orthokeratology contact lens wear or bifocal/PAL spectacle wear (longer than 1 month of wear)
* Previous or current participation in myopia control studies
* Chronic use of medications that may affect immunity, such as oral or ophthalmic corticosteroids for ocular or systemic diseases
* Issues that may interfere with the ability to participate over the next 3 years
B: Children with myopia who are able to adapt to rigid contact lens wear
C: Inclusion Criteria:

* 6 to 11 years of age
* Best corrected vision of at least 20/30 in each eye
* Birth weight \> 1250g

(The criteria below will be evaluated at a screening visit to find out if the child can participate)

* Accommodative lag \>= 1.30 D (for a 4D stimulus)
* At least -0.75 D myopia in each meridian measured with cycloplegic autorefraction but not more than -4.50 D in each meridian in each eye
* Esophoria at near if more than -2.25 D spherical equivalent (high myopia)
* Astigmatism \< 2.00 DC in each eye
* Anisometropia \< 2.00 D

Exclusion Criteria:

* Strabismus (eye turn)
* History of contact lens wear
* History of previous bifocal wear
* Diabetes mellitus
D: Myopic volunteers, ages 20 to 35, who had not worn contact lenses were eligible to participate in the study if they were free of ocular disease, were in good physical health, and were not taking systemic medications that could have ocular side effects. In addition, eligibility was limited to persons with corneal curvature between 40.50 and 47.00 D (flatter keratometry reading), corrected visual acuity of 6/6 (20/20) or better in each eye, astigmatism less than 0.75 D, anisometropia less than 1 D, and myopia between 1 and 4 D.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Noninvasive Ventilation Strategies for Early Treatment of RDS in Preterm Infants: An RCT
Brief Summary: The purpose of this study is to determine whether two different strategies of Non Invasive Ventilation (NIV) have different effect on length and failure of NIV support in preterm infants with respiratory distress syndrome (RDS).


Options:
A: Inclusion Criteria:

* preterm infants with RDS
* assigned to non invasive ventilation

Exclusion Criteria:

* preterm on endotracheal ventilation
* severe congenital pulmonary or cardiovascular malformation
B: Inclusion Criteria:

* Preterm with a weight less than 1501 g
* Gestational age less or equal to 34 weeks
* Preterm that meets extubation criteria after at least 2 hours and less than 14 days connected to mechanical ventilation
* Patient receiving methylxanthynes

Exclusion Criteria:

* Patient more than 14 days in mechanical ventilation
* Newborn with congenital cardiopathy
* Newborn with congenital malformation
* Newborn wirh chromosomopathy or genopathic disease
* Newborn with suspected gastrointestinal disease
* Newborn with neuromuscular disease or receiving muscle relaxants
* Lack or informed consent signed by parents or legal representative
C: Inclusion Criteria:

1. Gestational age between 24 to 34 and 6/7 weeks assessed by the obstetrical team from dating of last menstural period or ultrasound and weight \>1000 g for the initial treatment of RDS or \<35 weeks post extubation or for apnea of prematurity
2. Infants with RDS who will need NRS as initial therapy or after extubation and for apnea of prematurity, 3. written informed consent.

Exclusion Criteria:

1. Significant morbidity apart from RDS including: cardiac disease (not including patent ductus arteriosus \[PDA\]), congenital malformation, or if they had cardiovascular or respiratory instability because of sepsis, anemia or severe intraventricular hemorrhage (IVH),
2. Parents refuse consent.
3. Unavailability of suitable ventilator.
D: Inclusion Criteria:

* All inborn VLBW infants (birthweight less than 1500 g and Gestational Age \< 32 wks) with signs of RDS, spontaneously breathing and only supported by N-CPAP, will be randomized within the first 2 hours of life to receive two different Non Invasive Ventilation (NIV) strategies.

Exclusion Criteria:

* Apneic or severely depressed newborns requiring invasive ventilation, within two hours from birth
* Newborns with genetic disease and/or with major congenital malformations
* Newborns for whom it was not obtained informed consent within two hours from birth

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Noninvasive Ventilation Strategies for Early Treatment of RDS in Preterm Infants: An RCT
Brief Summary: The purpose of this study is to determine whether two different strategies of Non Invasive Ventilation (NIV) have different effect on length and failure of NIV support in preterm infants with respiratory distress syndrome (RDS).


Options:
A: Inclusion Criteria:

* Birth weight \<1000 gm
* Gestational age \<30 completed weeks
* Intention to manage the infant with non-invasive respiratory support (i.e. no endotracheal tube), where either:

  * the infant is within the first 7 days of life and has never been intubated or has received less than 24 hours of total cumulative intubated respiratory support;
  * the infant is within the first 28 days of life, has been managed with intubated respiratory support for 24 hours or more and is a candidate for extubation followed by non-invasive respiratory support.

Exclusion Criteria:

* Considered non-viable by clinician (decision not to administer effective therapies)
* Life-threatening congenital abnormalities including congenital heart disease (excluding patent ductus arteriosis)
* Infants known to require surgical treatment
* Abnormalities of the upper and lower airways
* Neuromuscular disorders
* Infants who are \>28 days old and continue to require mechanical ventilation with an endotracheal tube
B: Inclusion Criteria:

* Infants \</= 1250 grams who are going to be extubated

Exclusion Criteria:

* Congenital abnormalities of the upper airway
* Acquired nasal septum injury
* Congenital Heart Disease excluding Patent Ductus arteriosus
C: Inclusion Criteria:

* All inborn VLBW infants (birthweight less than 1500 g and Gestational Age \< 32 wks) with signs of RDS, spontaneously breathing and only supported by N-CPAP, will be randomized within the first 2 hours of life to receive two different Non Invasive Ventilation (NIV) strategies.

Exclusion Criteria:

* Apneic or severely depressed newborns requiring invasive ventilation, within two hours from birth
* Newborns with genetic disease and/or with major congenital malformations
* Newborns for whom it was not obtained informed consent within two hours from birth
D: Inclusion Criteria:

* preterm infants with RDS
* assigned to non invasive ventilation

Exclusion Criteria:

* preterm on endotracheal ventilation
* severe congenital pulmonary or cardiovascular malformation

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effects of Clinical Music Improvisation on Resiliency in Adults Undergoing Infusion Therapy
Brief Summary: This study will investigate the impact of music therapy on newly diagnosed patients with cancer undergoing chemotherapy. Measurements used at baseline, middle and end of first cycle will be the Resiliency Scale (Wagnild and Young 1993); The HADS scale (hospital anxiety depression scale, Zigmond and Snaith 1983 )and and The CAS scale for pain (Color Analysis Scale).


Options:
A: Inclusion Criteria:

* 18 and older
* diagnosed with breast cancer, lung cancer, or gastro-intestinal cancer

Exclusion Criteria:

* Under 18
* past cancer(s)
B: Inclusion Criteria:

* Diagnosed with depressive or anxiety disorder due to another medical condition in the context of cancer or palliative care
* competence to consent and participate
* speak and read English
* consistent and reliable access to the internet

Exclusion Criteria:

* acute hypomanic/manic episodes
* acute psychosis
* severe alcohol or substance use disorder
* active suicidal or homicidal ideation
* received CBT in the past year or are currently receiving CBT
C: INCLUSION CRITERIA:

* Diagnosis of incurable solid tumor cancers
* At least four weeks post-diagnosis
* Current symptoms of anxiety and anxiety as principal psychiatric problem

  * Patients with co-morbid depression are eligible as long as anxiety symptoms are primary
  * Concurrent pharmacotherapy for anxiety allowed

EXCLUSION CRITERIA:

* Delirium or dementia
* Active and untreated major psychiatric condition such as schizophrenia or bipolar disorder, other psychotic disorders, or substance dependence
* Other inability to complete informed consent process or study procedures
D: Inclusion Criteria:

1. Teenagers at the ages 12-17
2. Four or five (dependent on their overall plan of medical treatment) consecutive courses of chemotherapy administrated at the involved child cancer units and (administered) over a period of minimum 24 hours incl. hydration with assumed moderate to severe nausea and vomiting.

   The specific type of chemotherapy may vary across the four/five consecutive courses but shall include one of the following moderate and/or highly emetogenic types of chemotherapy:

   Moderate emetogenic chemotherapy:
   * Carboplatin
   * Cyclophosphamide \<1500 mg/m2
   * Cytarabine \>1 g/m2
   * Daunorubicin
   * Doxorubicin
   * Epirubicin
   * Idarubicin
   * Ifosfamide
   * Mitoxantrone
   * Methotrexate \>1000 mg/m2

   Highly emetogenic chemotherapy:
   * Cisplatin \>25 mg/m2
   * Cyclophosphamide \>1500 mg/m2
   * Dacarbazine
3. Understand Norwegian/Danish
4. Read Norwegian/Danish (teenagers or alternatively parents)
5. No significant hearing impairment
6. Informed written consent (teenagers ≥16 years and parents)
7. Subsequent verbal confirmation of written informed consent before enrolment in study

Exclusion Criteria:

1. Previous and/or acute psychiatric diagnosis
2. Cognitive and mental deficits or impaired functioning

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Integrative Medicine Group Visits: A Patient-Centered Approach to Reducing Chronic Pain and Depression in a Disparate Urban Population
Brief Summary: The purpose of this study is to determine whether Integrative Medicine Group Visits (IMGV) are effective for treating patients with chronic pain and depression.


Options:
A: Inclusion Criteria:

* self-reported chronic pain for at least 12 weeks
* average pain intensity for the previous week \>4 on a 0 to 10 numerical rating scale; PHQ-9 score \>5, indicating minor depression or greater
* English fluency sufficient to follow treatment instructions and answer survey questions.

Exclusion Criteria:

* previous participation in IMGV
* new pain treatments in past month or anticipated to begin in next 3 months
* active or planned worker's compensation, disability, or personal injury claims
* known or planned pregnancy
* manic symptoms
* active suicidality
* psychotic symptoms
* no PCP
B: Inclusion criteria

* RA as defined by the American College of Rheumatology
* English literacy and fluency

Exclusion criteria

* Major medical condition or illness which limits life expectancy or results in severe symptoms or functional disability (Duke Severity of Illness score \> 0.85)
* Fibromyalgia
* Received or currently receiving psychosocial treatment for RA
* Unavailability for Month 12 follow-up
C: Inclusion Criteria:

* fibromyalgia according to the criteria of the American College of Rheumatology (ACR)

Exclusion Criteria:

* physical or psychological comorbidity that interferes with cognitive-behavioral treatment
* participation in other clinical trials
* other psychological treatments
* pregnancy
* illiteracy
* difficulties with understanding Dutch language
D: Inclusion Criteria:

* Patients with aged between 18-75 years-old who meet the diagnostic criteria of fibromyalgia established by the American College of Rheumatology (ACR)

Exclusion Criteria:

* Patients with a diagnosis not based on the ACR criteria
* Those with cognitive impairment or suffering from physical mental/psychiatric limitations
* Severe concurrent rheumatologic illness that impede participation in the study evaluations
* Those who are not expected to live at least 12 months
* Those without schooling.

Answer: A